CRKL acts as tumour promotor and miR‐429 acts as a tumour suppressor in CML, their dysexpressions are involved in the carcinogenesis and progression of CML. The gene discussed is CRKL; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.